1. Home
  2. ASM vs ABUS Comparison

ASM vs ABUS Comparison

Compare ASM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avino Silver & Gold Mines Ltd. (Canada)

ASM

Avino Silver & Gold Mines Ltd. (Canada)

HOLD

Current Price

$5.62

Market Cap

964.0M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.38

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASM
ABUS
Founded
1968
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
964.0M
839.5M
IPO Year
2005
2008

Fundamental Metrics

Financial Performance
Metric
ASM
ABUS
Price
$5.62
$4.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$8.18
$5.00
AVG Volume (30 Days)
3.1M
2.7M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$53.35
N/A
Revenue Next Year
$34.26
$239.71
P/E Ratio
$67.93
$5.14
Revenue Growth
N/A
128.21
52 Week Low
$3.10
$3.25
52 Week High
$11.99
$5.38

Technical Indicators

Market Signals
Indicator
ASM
ABUS
Relative Strength Index (RSI) 43.49 43.60
Support Level $5.44 $4.16
Resistance Level $5.87 $4.69
Average True Range (ATR) 0.34 0.24
MACD 0.00 -0.06
Stochastic Oscillator 29.30 11.95

Price Performance

Historical Comparison
ASM
ABUS

About ASM Avino Silver & Gold Mines Ltd. (Canada)

Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: